Skip to main content
Equibles
IMNN logo

IMNN · Imunon, Inc. · Metrics

Track IMNN — free

Use IMNN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IMNN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.83 -0.05 (-5.26%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Based on the above, management has determined there is substantial doubt regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$4.92M
Shares
5.61M
Volume · Oct 28 195.02K Avg daily vol (3M) 113.97K

IMNN metrics

74 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.83
Market cap
$4.92M

Price action

20 metrics
Price change (1W)
-12.8%
Price change (30D)
-36.5%
Price change (3M)
-42.7%
Price change (6M)
-68.1%
Price change (YTD)
-77.0%
Price change (1Y)
-81.4%
Trailing year
Price change (5Y)
—
52-week high
$4.72
52-week low
$0.88
Change from 52-week high
-81.4%
Change from 52-week low
+0.0%
Annualized volatility
63.7%
Annualized volatility (3M)
83.6%
Beta
0.6
RSI (14D)
31.0
Price vs SMA 50
-35.4%
Price vs SMA 200
-61.5%
Avg volume (3M)
111,458
Relative volume
4.9
Average dollar volume
$153,341

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
5.61M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-39.7×
EV / EBITDA
—
EV / EBIT
—
P / sales
13.8×
reciprocal yield 7.2%
P / book
1.6
reciprocal yield 60.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-213.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
24.6×
reciprocal yield 4.1%
EV / revenue historical average (5Y)
30.0×
reciprocal yield 3.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
-4,984.3%
Trailing 12 months
Net margin
-7,179.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$14.84M
Net income (TTM)
−$14.72M
Trailing 12 months
Diluted EPS (TTM)
$-2.91
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-4.02
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-3.98
Operating cash flow per diluted share (TTM)
$-4.12
Free cash flow per diluted share (TTM)
$-7.46
Capital expenditures per diluted share (TTM)
$0.21
R&D per diluted share (TTM)
$2.24
Stock compensation per diluted share (TTM)
—
Book value per share
$2.07

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$500,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+309.7%
Year over year · more shares
Revenue CAGR (3Y)
+0.0%
Revenue CAGR (5Y)
+0.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-351.3%
Return on assets
-98.2%
Debt / equity
—
Current ratio
1.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$6.86M
Total assets
$14.99M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$15.11M
Capital expenditures (TTM)
$72,669
R&D (TTM)
$8.19M
SG&A (TTM)
—
Stock compensation (TTM)
$442,071
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
23
13F filer change QoQ
+4
Institutional ownership
5.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
4.0%
Private-fund adviser ownership
3.4%
Active holders' share change QoQ
-47.6%
Holder tenure
4.9
Price vs estimated holder cost
-53.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.3%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
25 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$11,919
Insider-sentiment score
42 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 749647 CUSIP 15117N701 13F (30d) 2 filings 2 filers Visit website Investor relations